Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens.

Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens.

<h4>Background</h4>Approximately 130 000 infants acquire HIV annually despite global maternal antiretroviral therapy scale-up. We evaluated the potential clinical impact and cost-effectiveness of offering long-acting, anti-HIV broadly neutralizing antibody (bNAb) prophylaxis to infants i...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher Alba, Shelly Malhotra, Stephanie Horsfall, Matthew E Barnhart, Adrie Bekker, Katerina Chapman, Coleen K Cunningham, Patricia E Fast, Genevieve G Fouda, Kenneth A Freedberg, Ameena Goga, Lusine R Ghazaryan, Valériane Leroy, Carlyn Mann, Margaret M McCluskey, Elizabeth J McFarland, Vincent Muturi-Kioi, Sallie R Permar, Roger Shapiro, Devin Sok, Lynda Stranix-Chibanda, Milton C Weinstein, Andrea L Ciaranello, Caitlin M Dugdale
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0318940
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pone.0318940

Similar Items